The study also identified similar 12-month outcomes between torsemide and furosemide regardless of heart failure (HF) type.
Among individuals discharged following hospitalization for heart failure (HF), newly developed or de novo HF demonstrated superior clinical and patient-reported results compared with worsening HF (WHF). Additionally, regardless of HF type, there were no notable variations in 12-month clinical or patient-reported outcomes between torsemide and furosemide.
These findings are based on a subanalysis of the Torsemide Comparison With Furosemide for Management of Heart Failure (TRANSFORM-HF) randomized clinical trial published in JAMA Cardiology.
Hospital corridor | Image credit: spotmatikphoto – stock.adobe.com
The substudy included 2858 patients with a documented ejection fraction who participated in the TRANSFORM-HF trial, which was conducted between June 2018 and March 2022. The current patient cohort had a mean (SD) age of 64.5 (14) years, and more than 60% were male. Of this group, 838 patients (29.3%) had de novo HF, and 2020 patients (70.7%) had WHF. Aside from the varying ratios of patients with each HF type, the de novo HF group also had a mean age 6 years younger than that of the WHF group, a higher glomerular filtration rate, lower levels of natriuretic peptides, and were generally discharged on lower doses of loop diuretic.
The study assessed all-cause mortality and hospitalization outcomes for a 12-month period and measured changes from the initial state in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS).
The main finding was that de novo HF was associated with lower all-cause mortality at 12 months, occurring in 65 (9.1%) of patients with newly developed HF compared with 408 (25.4%) of patients with WHF (adjusted HR [aHR], 0.50; 95% CI, 0.38-0.66; P < .001). Patients with de novo HF also experienced a reduced incidence of all-cause first rehospitalization at 12 months, as well as greater improvement from baseline in KCCQ-CSS at 12 months, with a median (IQR) score of 29.94 (27.35-32.54) compared with 23.68 (21.62-25.74) for patients with WHF. The adjusted estimated difference in means was 6.26 (95% CI, 3.72-8.81; P < .001).
Looking at the difference between the 2 drugs, the researchers found no significant difference in mortality between torsemide and furosemide in either patients group. For the de novo group, the number of events per 100 patient-years was 27 (7.4%) for torsemide and 38 (10.9%) for furosemide (aHR, 0.70; 95% CI, 0.40-1.14; P = .15). For the WHF group, these rates were 212 (26.8%) for torsemide and 196 (24.0%) for furosemide (aHR, 1.08; 95% CI, 0.89-1.32; P = .42; P for interaction = .10). The study also did not demonstrate any significant differences in hospitalization, first all-cause hospitalization, or total hospitalization at 12 months between the drugs in either de novo HF or WHF.
The study also revealed generally low (2.8%) rate of discontinuation of diuretics at discharge, with no significant differences between de novo HF and WHF cases. However, patients with de novo HF exhibited a consistent increase in loop diuretic discontinuation at month 1 (6.5%), month 6 (9.1%), and month 12 (12.9%).
Although there was a nominally significant decrease in mortality observed at the 12-month mark among the torsemide group in patients with de novo HF and an ejection fraction of 40% or less—with a significant interaction P value of 0.03—the infrequent occurrence of events in these patients and the absence of a similar pattern in other clinical endpoints suggest that this isolated finding is likely due to chance and, as a result, lacks clinical significance.
The authors acknowledged that factors like sample size, crossover rates, and discontinuation of diuretics during the follow-up period could potentially affect the results. Additionally, despite making statistical adjustments, there remains the possibility of residual or unmeasured confounding influencing the study outcomes.
Reference
Krim SR, Anand S, Greene SJ, et al. Torsemide vs furosemide among patients with new-onset vs worsening chronic heart failure: a substu dy of the TRANSFORM-HF randomized clinical trial. JAMA Cardiol. Published online November 13, 2023. doi:10.1001/jamacardio.2023.4776
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Study: SGLT2is Should Be Continued Despite Initial eGFR Decline in Patients With HFmrEF/HFpEF
December 6th 2023Despite an initial drop in estimated glomerular filtration rate (eGFR) after 1 month of dapagliflozin, researchers say this is not associated with subsequent risk of cardiovascular or kidney events for patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF).
Read More